Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Positive BLINCYTO® (blinatumomab) Phase 2 Study Results In Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia

[PR Newswire] – THOUSAND OAKS, Calif., July 16, 2015 /PRNewswire/ — Amgen (AMGN) today announced the top-line results of a Phase 2 open-label, single-arm, multicenter trial to evaluate the efficacy and safety of . . . → Read More: Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Positive BLINCYTO® (blinatumomab) Phase 2 Study Results In Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia Similar Articles: Stock Update: Amgen Inc (NASDAQ:AMGN) – FDA panel backs Amgen’s cholesterol drug for high-risk patients Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen’s Repatha effective; question is for which patients–FDA Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen To Advance Understanding Of The Treatment Of Blood Cancers At 20th Congress of European Hematology Association (EHA)